The Society of Infectious Diseases Pharmacists applauds the recent revision of the Paxlovid (nirmatrelvir and ritonavir) Emergency Use Authorization (EUA) that authorizes pharmacists to prescribe Paxlovid. We thank the FDA, the White House, and Coronavirus Response Coordinator Dr. Ashish Jha, for making meaningful changes to the EUA that will increase access to oral antiviral therapy for COVID-19 infections. We are especially proud of the SIDP leaders and members who have been persistent in advocating for expanded access of Paxlovid through pharmacist prescribing in an effort to improve patient care.

Under the new revision, licensed pharmacists may prescribe Paxlovid to patients who are positive for COVID-19, at high risk for progression of symptom severity, and have sufficient information to evaluate the patient’s renal and hepatic function and potential for drug interactions. Additional information from the FDA can be found here. Frequently asked questions prepared by the FDA about the updated Paxlovid EUA can be found here.

While we celebrate this step forward, the conditions of the EUA continue to leave the medically underserved population vulnerable as they are less likely to meet the conditions for pharmacist prescribing. In particular, the requirement for recent health records or laboratory data presents potential barriers to access COVID-19 therapies. SIDP remains committed to reducing disparities in healthcare for patients in underserved and minoritized communities. We will continue to work with government agencies and partner organizations to improve health equity.

Since March of 2020, SIDP has provided vital educational resources for pharmacists and other healthcare professionals related to therapies for COVID-19 treatment and prevention. Paxlovid specific education is being updated and will be available on the SIDP COVID-19 resource website soon.